BC Cancer, Vancouver, Vancouver, BC, V5Z 4S6, Canada.
Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, V5Z 4S6, Canada.
Future Oncol. 2021 Jul;17(19):2413-2429. doi: 10.2217/fon-2020-1245. Epub 2021 Mar 26.
Recent innovations in the treatment of metastatic prostate cancer have improved patient outcomes. Nonetheless, this disease remains fatal and additional treatment approaches are needed. Greater understanding of the molecular landscape of metastatic prostate cancer has revealed recurrent alterations in key pathways amenable to therapeutic targeting. One such pathway is DNA repair, particularly alterations in genes directly or indirectly associated with homologous recombination repair found in up to one-quarter of patients with metastatic castrate-resistant prostate cancer (mCRPC). Olaparib, an inhibitor of poly-ADP-ribose polymerase, has recently gained approval for the treatment of mCRPC harboring alterations in homologous recombination repair genes. This review will provide a summary of evidence regarding PARP inhibition in the treatment of mCRPC, with a specific focus on olaparib.
最近在转移性前列腺癌的治疗方面的创新提高了患者的治疗效果。然而，这种疾病仍然是致命的，需要额外的治疗方法。对转移性前列腺癌分子图谱的进一步了解揭示了关键通路的反复改变，这些改变可以通过治疗靶向来治疗。这样的途径之一是 DNA 修复，特别是在多达四分之一的转移性去势抵抗性前列腺癌（mCRPC）患者中发现的与同源重组修复直接或间接相关的基因的改变。聚 ADP 核糖聚合酶抑制剂奥拉帕利最近获得批准用于治疗携带同源重组修复基因改变的 mCRPC。本综述将提供 PARP 抑制在 mCRPC 治疗中的证据总结，重点是奥拉帕利。
